Hub : Traits :

Age when periods started (menarche)

796 significantly associated models · 251 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 41130424 42542658 1 1 2.9e-07 3.7e-06 7.2e-01 99 FOXO6
2 1 43042125 45137893 9 2 2.9e-11 2.5e-11 4.7e-01 99 DPH2 MED8
3 1 65189751 66803080 2 1 2.7e-10 7.8e-10 1.0e-01 93 LEPROT
4 1 71163715 73435171 1 1 2.6e-14 3.1e-13 2.9e-02 91 NEGR1
5 1 73966076 75395327 1 1 5.7e-12 3.3e-27 3.6e-18 35 FPGT
6 1 149880483 151715279 2 2 1.1e-07 1.5e-05 6.8e-01 99 C1orf56 ENSA
7 1 153431561 154861187 1 1 3.3e-07 2.0e-05 1.3e-04 19 TPM3
8 2 15703 963334 1 1 1.9e-09 7.8e-20 9.0e-16 22 SH3YL1
9 2 24348096 25837917 2 1 9.6e-10 1.5e-08 1.7e-02 82 ADCY3
10 2 47224927 48727280 1 1 9.5e-09 2.8e-09 1.2e-01 93 MSH6
11 2 60284614 62394127 6 2 2.8e-13 3.5e-12 4.7e-02 92 LOC339803 PUS10
12 2 152811852 154267276 1 1 2.2e-13 1.5e-12 1.0e+00 100 PRPF40A
13 2 199443880 201021954 1 1 1.5e-23 1.4e-23 1.0e+00 100 SATB2
14 2 202540420 204433184 2 1 3.5e-08 4.6e-07 8.2e-01 100 RP11-686O6.2
15 3 48335857 53778875 48 3 4.1e-13 6.8e-11 9.3e-02 93 DAG1 HEMK1 TMEM110
16 3 87508781 88901377 1 1 3.5e-07 1.6e-06 4.4e-02 82 C3orf38
17 3 127271320 128821807 1 1 1.8e-08 1.2e-08 2.3e-01 96 EEFSEC
18 3 155695485 157118526 1 1 1.1e-07 1.2e-07 1.0e+00 100 TIPARP
19 4 94527983 95955095 1 1 2.4e-10 1.5e-10 1.0e+00 100 HPGDS
20 4 103020804 104487361 1 1 3.3e-07 5.2e-09 3.6e-10 -15 UBE2D3
21 5 133164490 134784086 3 2 3.3e-17 3.9e-22 6.1e-06 78 PHF15
22 6 41005502 42598371 4 10 3.0e-10 1.6e-10 1.0e+00 100 BYSL MED20 PRICKLE4
23 6 54344853 55832161 1 1 6.6e-08 8.8e-11 2.5e-04 68 HCRTR2
24 6 56123698 57687035 3 1 1.3e-10 1.8e-10 1.8e-02 86 RP11-203B9.4
25 6 75612601 77124675 1 1 1.6e-07 4.7e-08 1.0e+00 100 SENP6
26 6 83573836 85117025 1 1 1.3e-09 9.8e-10 1.4e-01 94 SNAP91
27 6 100257579 102026932 2 1 1.1e-10 4.1e-12 4.9e-03 84 RP3-467N11.1
28 6 104478130 106323464 4 9 7.9e-77 1.1e-112 NaN NaN BVES HACE1 LIN28B POPDC3
29 6 108183628 109704062 1 1 1.4e-07 2.2e-10 3.4e-04 68 FOXO3
30 6 125970401 127355237 1 1 3.5e-16 1.3e-16 1.0e+00 100 CENPW
31 6 146826657 148410391 2 1 2.6e-08 2.2e-08 2.8e-01 96 STXBP5
32 6 151030107 152470136 1 1 8.6e-09 1.3e-08 1.8e-02 83 RMND1
33 7 32098935 33489728 1 1 3.0e-07 2.9e-06 2.0e-01 92 RP11-225B17.2
34 7 73425238 75842792 14 5 4.8e-13 3.3e-10 NaN NaN PMS2P3 POM121C STAG3L2
35 7 99008415 100411278 1 1 2.4e-07 8.8e-07 2.0e-01 93 TAF6
36 9 107767036 109216841 1 1 2.8e-20 1.2e-62 7.7e-45 29 TMEM38B
37 9 110998007 112628478 5 2 1.3e-09 1.6e-09 1.0e+00 100 C9orf4 CTNNAL1
38 9 126844856 128643415 2 2 2.1e-10 2.1e-11 6.2e-02 92 OLFML2A PPP6C
39 10 64195778 65606229 1 1 8.7e-08 4.6e-07 3.7e-01 97 NRBF2
40 10 96682514 98113333 1 1 3.7e-09 3.6e-17 8.8e-13 28 ALDH18A1
41 10 122989048 124407934 1 1 1.4e-07 1.9e-06 6.8e-03 68 RP11-500G22.2
42 11 7714238 9679183 4 1 7.4e-13 1.8e-15 1.7e-04 78 RP11-152H18.3
43 11 12611333 14105497 1 1 6.7e-08 5.2e-15 1.5e-08 48 ARNTL
44 11 16532857 18068163 1 1 7.8e-11 1.1e-10 1.8e-05 56 NUCB2
45 11 27433832 29054545 1 1 3.2e-07 4.1e-11 6.4e-13 -19 METTL15
46 11 42881882 44596817 2 1 5.1e-09 2.0e-10 6.7e-04 71 RP11-613D13.5
47 11 46543524 48485877 9 1 4.5e-13 1.7e-09 6.2e-02 90 MADD
48 11 64721908 66333072 4 1 2.8e-08 6.6e-08 1.0e+00 100 CTSW
49 11 77027574 78979645 4 1 1.0e-09 6.7e-10 6.9e-03 81 GAB2
50 11 100624096 102570548 2 1 4.8e-17 1.3e-18 1.0e+00 100 TRPC6
51 11 122058476 123525464 1 2 2.6e-32 4.2e-33 1.0e+00 100 C11orf63
52 12 48605088 50000387 1 1 1.4e-07 5.4e-07 2.3e-01 94 CCDC65
53 12 120502726 122037099 1 1 1.8e-07 1.2e-07 7.8e-03 75 SPPL3
54 13 39533590 41063028 1 2 1.6e-07 1.8e-09 4.8e-03 78 COG6
55 14 60168943 61664530 1 1 2.5e-10 2.1e-15 6.6e-07 61 C14orf39
56 14 99920745 101533384 2 2 2.4e-07 7.1e-16 2.9e-09 46 DEGS2 WARS
57 15 40778506 42301497 3 1 1.2e-10 5.3e-12 1.4e-02 87 CHP
58 15 59941722 61470359 2 1 2.8e-10 2.3e-17 4.1e-10 46 ANXA2
59 15 63687200 65137171 1 1 3.0e-07 4.0e-07 1.0e+00 100 SNX1
60 15 67138238 68789191 1 1 1.2e-09 1.9e-09 4.1e-02 88 MAP2K5
61 15 88358250 89773505 1 1 3.9e-13 1.2e-13 4.6e-02 93 DET1
62 16 13697975 14759768 1 1 2.0e-08 1.9e-19 1.2e-12 38 RP11-65J21.3
63 16 19022448 20596558 3 1 3.0e-10 1.2e-09 1.0e+00 100 GPRC5B
64 16 28825605 31026427 20 1 5.1e-12 2.8e-09 1.7e-01 95 ASPHD1
65 16 52828325 54235440 1 1 3.8e-09 1.7e-38 4.5e-31 20 AKTIP
66 16 68901284 70840490 9 3 1.7e-16 3.8e-23 4.7e-01 100 NFAT5 WWP2
67 17 42413481 43570226 1 1 1.5e-07 8.8e-08 1.5e-01 93 DCAKD
68 17 52350677 54097059 3 1 1.6e-10 1.8e-10 3.1e-01 97 HLF
69 18 2912920 4304557 1 1 8.1e-11 1.1e-11 7.0e-03 84 DLGAP1-AS2
70 18 43698447 46153595 5 2 4.9e-17 2.6e-24 7.0e-06 80 HDHD2 PIAS2
71 19 588305 2560423 5 2 1.0e-11 4.8e-11 3.5e-01 98 KLF16 REXO1
72 19 9223787 11140703 4 1 4.0e-20 4.0e-20 1.0e+00 100 CTD-2623N2.11
73 19 12309739 13720731 1 1 2.0e-07 3.8e-06 9.3e-01 100 GCDH
74 19 14764742 16186772 1 1 2.7e-07 2.5e-07 1.0e+00 100 AKAP8
75 19 35434238 37300554 8 2 2.9e-11 1.0e-11 6.7e-03 84 C19orf55 RN7SL765P
76 21 39849553 41498432 5 1 2.7e-15 1.1e-13 1.9e-02 90 PSMG1
77 22 21798199 23032448 4 3 1.6e-08 5.6e-08 1.0e+00 100 LL22NC03-86G7.1 TOP3B YPEL1
78 22 31195775 32708691 1 1 2.4e-07 1.4e-07 9.7e-04 61 SFI1

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Alzheimer’s Disease (including proxy) 1.51 1 0 0.0 0.00 1.0e+00 TAF6
Crohns Disease (2017) 1.16 3 1 3.0 0.00 1.0e+00 ADCY3 AKAP8 STAG3L2
Irritable Bowel Disease (IBD) 1.36 4 2 6.1 -0.15 8.5e-01 ADCY3 DAG1 SATB2 STAG3L2
Ulcerative Colitis (UC) 1.43 3 2 6.1 0.00 1.0e+00 ADCY3 DAG1 SATB2
Major Depression (MDD) 1.72 2 1 3.0 0.00 1.0e+00 NEGR1 TPM3
Reaction Time 1.77 4 2 6.1 -0.42 5.8e-01 ADCY3 CCDC65 FOXO3 SNAP91
Verbal and Numeric Reasoning (VNR) 1.92 11 4 12.1 0.47 1.5e-01 ADCY3 CCDC65 CENPW DAG1 FOXO3 FOXO6 MADD MED8 NEGR1 TMEM110 WWP2
Breast Cancer 1.14 5 2 6.1 0.36 5.5e-01 ADCY3 AKTIP CTSW HCRTR2 HLF
Prostate Cancer 1.93 2 2 6.1 0.00 1.0e+00 EEFSEC TPM3
Age at First Birth 1.73 2 2 6.1 0.00 1.0e+00 DAG1 PHF15
Body Mass Index (BMI) (2010) 3.36 7 6 18.2 0.98 1.5e-05 ADCY3 AKTIP GPRC5B MADD MAP2K5 NEGR1 PMS2P3
Crohns Disease (2012) 1.13 1 0 0.0 0.00 1.0e+00 ADCY3
HDL Cholesterol 1.43 2 1 3.0 0.00 1.0e+00 MADD NRBF2
Rheumatoid Arthritis 1.23 1 0 0.0 0.00 1.0e+00 COG6
Schizophrenia 1.62 6 1 3.0 -0.54 2.7e-01 ASPHD1 DPH2 LIN28B NUCB2 SNAP91 TMEM110
Triglycerides 1.39 1 1 3.0 0.00 1.0e+00 NRBF2
Ulcerative Colitis 1.34 2 0 0.0 0.00 1.0e+00 DAG1 SATB2
Blood Eosinophil Count 1.02 15 9 27.3 -0.14 6.2e-01 ADCY3 ANXA2 ASPHD1 COG6 CTSW ENSA HEMK1 LOC339803 NUCB2 REXO1 RMND1 SFI1 SPPL3 TMEM110 WWP2
Blood Platelet Count 1.54 22 14 42.4 -0.23 3.0e-01 AKAP8 C3orf38 CTSW DCAKD EEFSEC GCDH GPRC5B HEMK1 HLF HPGDS LOC339803 MED20 MSH6 NRBF2 NUCB2 PHF15 PSMG1 RP11-686O6.2 SNX1 SPPL3 TIPARP TPM3
Blood Red Count 6.89 23 17 51.5 0.54 2.1e-03 ARNTL ASPHD1 BYSL C3orf38 CENPW CHP DAG1 GCDH HLF LL22NC03-86G7.1 MED20 MED8 NFAT5 NRBF2 PMS2P3 PRICKLE4 SNX1 SPPL3 TAF6 TIPARP TMEM110 TOP3B WWP2
Blood White Count 1.19 13 9 27.3 -0.06 8.5e-01 ADCY3 CENPW CHP DAG1 ENSA LEPROT MADD NRBF2 NUCB2 SPPL3 STXBP5 TIPARP UBE2D3
Heel T-Score 1.58 22 12 36.4 0.37 5.8e-02 ASPHD1 C11orf63 C14orf39 CCDC65 DAG1 DCAKD DET1 ENSA GAB2 GPRC5B HACE1 LIN28B MADD MSH6 NEGR1 PRPF40A RMND1 RP11-500G22.2 RP11-686O6.2 SATB2 STAG3L2 TIPARP
BMI 4.78 36 29 87.9 0.70 8.1e-07 ADCY3 AKTIP ARNTL ASPHD1 BYSL C1orf56 C3orf38 CTSW DAG1 FOXO3 FPGT GAB2 GPRC5B HEMK1 KLF16 LEPROT MADD MAP2K5 NEGR1 NFAT5 NRBF2 PHF15 PIAS2 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 RP3-467N11.1 SENP6 SNAP91 STAG3L2 TMEM110 WWP2
Height 2.77 52 46 139.4 -0.66 1.1e-09 ADCY3 ASPHD1 BVES BYSL C11orf63 C14orf39 C19orf55 C1orf56 C9orf4 CENPW CHP COG6 CTSW DCAKD DET1 DLGAP1-AS2 ENSA FOXO3 FOXO6 GCDH GPRC5B HACE1 HDHD2 HEMK1 LIN28B LL22NC03-86G7.1 MADD MED20 MED8 NFAT5 NRBF2 NUCB2 OLFML2A PHF15 PIAS2 PMS2P3 POPDC3 PRICKLE4 RMND1 RN7SL765P RP11-203B9.4 RP11-500G22.2 RP11-65J21.3 RP11-686O6.2 SENP6 SFI1 SH3YL1 SNAP91 SPPL3 TMEM38B TOP3B WWP2
Waist Hip Ratio (WHR) 2.12 13 7 21.2 -0.01 9.6e-01 BYSL C14orf39 C9orf4 CENPW CHP CTNNAL1 HEMK1 MED20 NFAT5 PPP6C SFI1 TIPARP TMEM110
Systolic Blood Pressure 1.64 14 8 24.2 0.29 2.9e-01 ADCY3 ARNTL CHP CTSW DCAKD DEGS2 FOXO3 KLF16 MED8 NUCB2 PMS2P3 POM121C STAG3L2 STXBP5
Smoking Status 2.40 10 6 18.2 0.13 7.2e-01 CTSW DAG1 DPH2 HACE1 MAP2K5 MED8 MSH6 PPP6C RP3-467N11.1 WWP2
Allergy or Eczema 1.63 5 3 9.1 0.38 5.3e-01 CHP DLGAP1-AS2 NEGR1 PUS10 SPPL3
Cardiovascular Disease 1.86 13 8 24.2 0.75 1.9e-03 ARNTL CHP CTSW DCAKD KLF16 MADD MAP2K5 NEGR1 NUCB2 PMS2P3 RP11-613D13.5 STAG3L2 TAF6
Hypothyroidism (self reported) 0.96 1 1 3.0 0.00 1.0e+00 MADD
Respiratory disease 1.38 4 2 6.1 0.50 5.0e-01 CHP DCAKD EEFSEC PSMG1
Type 2 Diabetes (T2D) 1.68 6 0 0.0 0.98 6.2e-04 AKTIP CENPW CTSW GCDH NFAT5 WWP2
Lung FEV1/FVC ratio 1.45 13 6 18.2 -0.02 9.5e-01 ADCY3 CENPW EEFSEC FOXO3 GAB2 HCRTR2 MSH6 NEGR1 NRBF2 PHF15 REXO1 RP11-686O6.2 TMEM110
Lung FVC 2.09 19 13 39.4 0.22 3.3e-01 BYSL C3orf38 CENPW CHP DAG1 ENSA FOXO3 FOXO6 HACE1 HEMK1 LIN28B MADD MAP2K5 MSH6 NFAT5 RP11-613D13.5 RP11-686O6.2 SATB2 WWP2
Neuroticism 1.60 6 3 9.1 -0.09 8.6e-01 ARNTL CENPW DAG1 GAB2 LIN28B MAP2K5
Chronotype (morning person) 2.50 10 5 15.2 -0.04 9.1e-01 AKTIP BYSL C14orf39 DAG1 ENSA HCRTR2 HEMK1 MADD MED20 PRICKLE4
Hair Pigment 0.26 8 6 18.2 -0.11 7.7e-01 ADCY3 CCDC65 CENPW FOXO3 GAB2 MADD MED20 NUCB2
Tanning 0.26 5 2 6.1 0.07 8.5e-01 ADCY3 BYSL GAB2 MED20 TMEM110
Hand grip strength (left) 1.58 5 2 6.1 0.64 1.7e-01 ADCY3 GPRC5B LIN28B MADD WWP2
Number of treatments/medications taken 1.86 4 1 3.0 -0.51 4.9e-01 DAG1 LIN28B NEGR1 STAG3L2
Sensitivity / hurt feelings 1.27 1 0 0.0 0.00 1.0e+00 DCAKD
Hearing difficulty/problems: Yes 1.24 1 0 0.0 0.00 1.0e+00 SATB2
Relative age of first facial hair 6.02 21 12 36.4 0.96 6.7e-18 ANXA2 BYSL C11orf63 DAG1 DCAKD DET1 DPH2 ENSA FOXO3 HACE1 HEMK1 HLF HPGDS LIN28B MED20 NRBF2 PRICKLE4 PSMG1 RP11-65J21.3 SATB2 SH3YL1
Other serious medical condition/disability diagnosed by doctor 1.47 1 0 0.0 0.00 1.0e+00 PRICKLE4
Systolic blood pressure, automated reading 1.83 12 3 9.1 -0.10 7.4e-01 ARNTL CHP CTSW DCAKD KLF16 MED8 NUCB2 PMS2P3 POM121C SH3YL1 STAG3L2 STXBP5
Supplements: Zinc 1.46 1 0 0.0 0.00 1.0e+00 NRBF2
Medication: Metformin 1.61 2 0 0.0 0.00 1.0e+00 GCDH SENP6
Pack years adult smoking proportion 1.53 1 0 0.0 0.00 1.0e+00 C3orf38
Impedance of leg (right) 3.35 28 18 54.5 0.36 3.6e-02 ADCY3 AKTIP ASPHD1 BYSL C14orf39 CCDC65 CTD-2623N2.11 CTNNAL1 CTSW DAG1 DCAKD DEGS2 GPRC5B HEMK1 KLF16 LIN28B LL22NC03-86G7.1 MADD MAP2K5 MED20 NEGR1 PHF15 PMS2P3 POM121C REXO1 SFI1 STAG3L2 TMEM110
Leg fat-free mass (left) 3.25 23 16 48.5 -0.03 8.5e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 C9orf4 CENPW CTSW DAG1 FOXO3 GPRC5B KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 TMEM110
Trunk fat percentage 2.82 20 11 33.3 -0.67 4.1e-04 ADCY3 AKTIP ARNTL ASPHD1 C11orf63 CENPW DCAKD FOXO3 MADD MAP2K5 NEGR1 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 SH3YL1 STAG3L2 WWP2
Hand grip strength (right) 1.54 6 1 3.0 0.69 8.5e-02 ADCY3 C14orf39 GPRC5B LIN28B REXO1 WWP2
Townsend deprivation index at recruitment 1.69 2 0 0.0 0.00 1.0e+00 KLF16 MAP2K5
Current tobacco smoking 1.66 3 0 0.0 0.00 1.0e+00 CCDC65 DPH2 PPP6C
Maternal smoking around birth 1.84 2 0 0.0 0.00 1.0e+00 DPH2 MED8
Fed-up feelings 1.36 2 0 0.0 0.00 1.0e+00 ARNTL DAG1
Relative age voice broke 6.96 18 6 18.2 0.98 2.3e-19 ANXA2 C11orf63 C19orf55 DET1 FOXO3 HACE1 HEMK1 HPGDS LIN28B MED20 PHF15 POM121C RP11-65J21.3 SATB2 SPPL3 STAG3L2 TMEM38B WWP2
Taking other prescription medications 2.00 2 1 3.0 0.00 1.0e+00 DAG1 STAG3L2
Heel bone mineral density (BMD) T-score, automated (left) 1.28 4 2 6.1 0.60 4.0e-01 C14orf39 LIN28B RP11-686O6.2 TIPARP
High blood pressure 2.02 15 5 15.2 -0.61 1.2e-02 ARNTL CHP DCAKD KLF16 MADD MAP2K5 NEGR1 NFAT5 NRBF2 NUCB2 PMS2P3 REXO1 RP11-613D13.5 STAG3L2 TAF6
Hayfever, allergic rhinitis or eczema 1.53 6 1 3.0 -0.49 3.3e-01 CHP DLGAP1-AS2 NEGR1 PUS10 SPPL3 TPM3
Sitting height 2.18 19 12 36.4 0.34 8.8e-02 ADCY3 BYSL C14orf39 CENPW CHP DPH2 ENSA FOXO3 FOXO6 LOC339803 MADD MED20 MED8 NFAT5 PHF15 RP11-65J21.3 SENP6 TIPARP WWP2
High blood pressure (mother) 1.34 1 0 0.0 0.00 1.0e+00 NUCB2
Body mass index (BMI) 4.47 29 24 72.7 -0.70 9.9e-06 ADCY3 AKTIP ARNTL ASPHD1 C3orf38 CTSW DAG1 FOXO3 GPRC5B HEMK1 KLF16 MADD MAP2K5 NEGR1 NFAT5 NRBF2 PHF15 PIAS2 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 SENP6 STAG3L2 TMEM110 WWP2
Impedance of leg (left) 3.29 25 17 51.5 0.37 3.8e-02 ADCY3 AKTIP ASPHD1 BYSL C3orf38 CTD-2623N2.11 CTSW DAG1 DCAKD DEGS2 GPRC5B HEMK1 KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 PHF15 PMS2P3 POM121C REXO1 SFI1 STAG3L2 TMEM110
Leg predicted mass (left) 3.27 23 16 48.5 -0.03 8.6e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 C9orf4 CENPW CTSW DAG1 FOXO3 GPRC5B KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 TMEM110
Trunk fat mass 3.08 27 15 45.5 -0.30 8.3e-02 ADCY3 AKTIP ARNTL ASPHD1 BYSL C11orf63 C14orf39 C3orf38 CTSW DAG1 FOXO3 GPRC5B KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 SH3YL1 STAG3L2 WWP2
Waist circumference 3.60 24 17 51.5 -0.63 3.8e-04 ADCY3 AKTIP ARNTL ASPHD1 C3orf38 C9orf4 CTSW DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 NEGR1 NFAT5 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 STAG3L2 TIPARP WWP2
Number of incorrect matches in round 1.23 1 1 3.0 0.00 1.0e+00 ASPHD1
Past tobacco smoking 2.21 8 1 3.0 0.04 9.3e-01 DAG1 DPH2 HACE1 MAP2K5 MSH6 PPP6C PSMG1 WWP2
Alcohol usually taken with meals 2.18 5 1 3.0 -0.76 1.4e-01 DPH2 MED8 NEGR1 NRBF2 PRICKLE4
Nervous feelings 1.60 5 0 0.0 0.62 2.6e-01 ARNTL ASPHD1 CENPW SATB2 TMEM110
Frequency of tenseness / restlessness in last 2 weeks 1.26 1 0 0.0 0.00 1.0e+00 DAG1
Hearing difficulty/problems with background noise 1.34 2 0 0.0 0.00 1.0e+00 LIN28B SNAP91
Hair/balding pattern: Pattern 2 1.53 1 0 0.0 0.00 1.0e+00 CENPW
Had menopause 1.41 1 0 0.0 0.00 1.0e+00 CHP
Forced vital capacity (FVC) 2.01 14 9 27.3 0.56 3.0e-02 ADCY3 CENPW FOXO6 HACE1 MADD NFAT5 PHF15 POPDC3 RP11-613D13.5 RP11-65J21.3 RP11-686O6.2 SATB2 SENP6 WWP2
Heel bone mineral density (BMD) T-score, automated (right) 1.24 4 2 6.1 0.99 1.5e-02 C14orf39 PRPF40A RP11-500G22.2 TIPARP
Ever unenthusiastic/disinterested for a whole week 1.37 1 0 0.0 0.00 1.0e+00 DAG1
Qualifications: None of the above 2.39 9 7 21.2 0.57 1.1e-01 C9orf4 CTNNAL1 DAG1 DPH2 FOXO3 MED8 NEGR1 NRBF2 PIAS2
Allergy 1.36 8 1 3.0 0.48 2.3e-01 CHP DCAKD EEFSEC NEGR1 PSMG1 PUS10 SPPL3 TPM3
Diabetes (self-reported) 1.81 3 1 3.0 0.00 1.0e+00 GCDH NFAT5 STAG3L2
Medication: Simvastatin 1.89 2 0 0.0 0.00 1.0e+00 BVES RP11-686O6.2
Fluid intelligence score 1.98 7 4 12.1 -0.57 1.8e-01 DAG1 DPH2 FOXO3 FOXO6 MADD MED8 NEGR1
Neuroticism score 1.40 2 1 3.0 0.00 1.0e+00 ARNTL UBE2D3
Weight 3.43 25 20 60.6 -0.26 1.4e-01 ADCY3 AKTIP ASPHD1 BYSL C14orf39 C3orf38 C9orf4 CENPW CTSW DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 MED20 NEGR1 PHF15 PMS2P3 POM121C REXO1 RMND1 RP11-152H18.3 RP11-613D13.5 STAG3L2
Impedance of arm (right) 3.32 32 23 69.7 0.66 8.1e-06 AKTIP ASPHD1 BVES C3orf38 CENPW CTD-2623N2.11 CTSW DAG1 DCAKD DLGAP1-AS2 EEFSEC FOXO3 GAB2 GPRC5B HACE1 HEMK1 KLF16 LIN28B MAP2K5 NEGR1 NRBF2 PHF15 PMS2P3 POM121C POPDC3 PSMG1 REXO1 RP3-467N11.1 SATB2 STAG3L2 TIPARP TMEM110
Arm fat percentage (right) 3.78 25 16 48.5 -0.67 8.2e-05 ADCY3 AKTIP ARNTL ASPHD1 C3orf38 CENPW CTSW DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 NEGR1 NFAT5 PHF15 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 STAG3L2 WWP2
Trunk fat-free mass 2.97 22 16 48.5 0.10 6.1e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B MED20 NEGR1 REXO1 RMND1 RP11-65J21.3 RP3-467N11.1 TMEM110 WARS
Hip circumference 3.39 22 19 57.6 -0.28 1.3e-01 ADCY3 AKTIP ASPHD1 BYSL C14orf39 C3orf38 DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 MED20 NEGR1 PHF15 PMS2P3 POM121C PSMG1 REXO1 RP11-613D13.5 STAG3L2 WWP2
Alcohol intake versus 10 years previously 1.34 3 1 3.0 0.00 1.0e+00 ASPHD1 DPH2 NEGR1
Worrier / anxious feelings 1.58 4 1 3.0 0.34 6.6e-01 ARNTL DPH2 SATB2 TMEM110
Frequency of tiredness / lethargy in last 2 weeks 1.58 2 1 3.0 0.00 1.0e+00 DAG1 HCRTR2
Hair/balding pattern: Pattern 3 1.19 2 1 3.0 0.00 1.0e+00 CENPW DCAKD
Forced expiratory volume in 1-second (FEV1) 1.70 12 7 21.2 0.46 1.1e-01 ADCY3 CENPW DAG1 FOXO6 HACE1 HDHD2 MADD NFAT5 PIAS2 POPDC3 RP11-65J21.3 WWP2
Pulse rate 1.43 2 0 0.0 0.00 1.0e+00 DAG1 TMEM110
Qualifications: A levels/AS levels or equivalent 1.85 7 5 15.2 -0.25 5.5e-01 DAG1 DPH2 MED8 NEGR1 NRBF2 PIAS2 PMS2P3
Serious illness, injury or assault of a close relative in last 2 years 1.23 1 0 0.0 0.00 1.0e+00 WWP2
Mouth/teeth dental problems: Dentures 1.78 3 0 0.0 0.00 1.0e+00 ADCY3 DAG1 LOC339803
Asthma 1.26 2 0 0.0 0.00 1.0e+00 EEFSEC SPPL3
Forced expiratory volume in 1-second (FEV1), Best measure 1.62 11 4 12.1 0.44 1.5e-01 ADCY3 CENPW DAG1 FOXO6 MADD NFAT5 PIAS2 POPDC3 RP11-65J21.3 SATB2 WWP2
Impedance of arm (left) 3.20 32 22 66.7 0.66 9.8e-06 AKTIP ASPHD1 BVES C3orf38 CENPW CTD-2623N2.11 CTSW DAG1 DCAKD DET1 DLGAP1-AS2 EEFSEC FOXO3 GAB2 GPRC5B HACE1 HEMK1 KLF16 LIN28B MAP2K5 NEGR1 NRBF2 PHF15 PMS2P3 POM121C POPDC3 REXO1 RP3-467N11.1 SATB2 STAG3L2 TIPARP TMEM110
Arm fat mass (right) 3.91 25 21 63.6 -0.47 6.0e-03 ADCY3 AKTIP ARNTL ASPHD1 BYSL C14orf39 C3orf38 CTSW DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 MED20 NEGR1 PHF15 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 STAG3L2 WWP2
Trunk predicted mass 2.98 23 16 48.5 0.09 6.5e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B LOC339803 MED20 NEGR1 REXO1 RMND1 RP11-65J21.3 RP3-467N11.1 TMEM110 WARS
Standing height 2.92 38 28 84.8 0.70 7.9e-09 ADCY3 ASPHD1 BVES BYSL C11orf63 C14orf39 C19orf55 CENPW CHP COG6 CTSW DCAKD DET1 ENSA FOXO3 FOXO6 GCDH HACE1 HDHD2 HEMK1 LIN28B MADD MED20 NFAT5 NRBF2 PHF15 PIAS2 PMS2P3 POPDC3 RMND1 RP11-203B9.4 RP11-500G22.2 RP11-65J21.3 RP11-686O6.2 SENP6 SNAP91 TMEM38B WWP2
Exposure to tobacco smoke at home 1.32 1 0 0.0 0.00 1.0e+00 DAG1
Seen doctor (GP) for nerves, anxiety, tension or depression 1.73 2 1 3.0 0.00 1.0e+00 DAG1 NEGR1
Hair/balding pattern: Pattern 4 1.31 2 2 6.1 0.00 1.0e+00 CENPW DCAKD
Birth weight of first child 1.50 3 0 0.0 0.99 8.5e-03 CHP PMS2P3 TIPARP
Peak expiratory flow (PEF) 1.40 4 1 3.0 0.21 7.9e-01 FOXO3 PPP6C RP11-65J21.3 WWP2
Ever highly irritable/argumentative for 2 days 1.32 1 0 0.0 0.00 1.0e+00 DAG1
Qualifications: O levels/GCSEs or equivalent 1.59 2 0 0.0 0.00 1.0e+00 DAG1 DPH2
Medication: Paracetamol 1.24 1 0 0.0 0.00 1.0e+00 DAG1
Medication for cholesterol, blood pressure or diabetes 1.73 2 0 0.0 0.00 1.0e+00 AKTIP TAF6
Glaucoma (self-reported) 1.43 1 1 3.0 0.00 1.0e+00 C14orf39
Gout (self-reported) 1.12 1 1 3.0 0.00 1.0e+00 WWP2
Hypothyroidism/myxoedema (self-reported) 0.84 1 0 0.0 0.00 1.0e+00 MADD
Medication: Amlodipine 1.52 1 0 0.0 0.00 1.0e+00 DEGS2
Birth weight 2.12 2 1 3.0 0.00 1.0e+00 CENPW TIPARP
Forced vital capacity (FVC), Best measure 2.06 14 7 21.2 0.57 2.6e-02 ADCY3 CENPW FOXO6 MADD NFAT5 PHF15 PIAS2 POPDC3 RP11-613D13.5 RP11-65J21.3 RP11-686O6.2 SATB2 SNAP91 WWP2
Body fat percentage 3.12 22 12 36.4 -0.63 6.9e-04 ADCY3 AKTIP ARNTL ASPHD1 C11orf63 C3orf38 CENPW CTSW DCAKD FOXO3 KLF16 MADD MAP2K5 NEGR1 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 STAG3L2 WWP2
Leg fat percentage (right) 3.17 24 13 39.4 -0.71 4.8e-05 ADCY3 AKTIP ARNTL ASPHD1 C3orf38 CENPW CTSW DAG1 DCAKD FOXO3 MADD MAP2K5 NEGR1 NRBF2 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 SENP6 STAG3L2 WWP2
Arm fat-free mass (right) 2.97 25 15 45.5 -0.06 7.5e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 CENPW CHP CTSW DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 RP3-467N11.1 TMEM110
Comparative body size at age 10 6.07 18 13 39.4 -0.77 4.4e-05 ADCY3 AKTIP ASPHD1 C11orf63 C3orf38 CCDC65 CTSW FPGT GPRC5B HACE1 LEPROT LIN28B LL22NC03-86G7.1 MADD MAP2K5 NEGR1 RP11-152H18.3 TOP3B
Worry too long after embarrassment 1.37 2 1 3.0 0.00 1.0e+00 ARNTL MAP2K5
Wheeze or whistling in the chest in last year 1.58 3 0 0.0 0.00 1.0e+00 ASPHD1 DAG1 DCAKD
Age at first live birth 1.62 3 1 3.0 0.00 1.0e+00 DAG1 DPH2 NRBF2
Qualifications: College or University degree 2.33 13 6 18.2 -0.35 2.2e-01 C9orf4 CENPW CTSW DAG1 DPH2 FOXO3 FOXO6 MED8 NEGR1 NRBF2 PMS2P3 POM121C RN7SL765P
Neck or shoulder pain in last month 1.76 1 0 0.0 0.00 1.0e+00 DAG1
Medication: Blood pressure 1.66 2 0 0.0 0.00 1.0e+00 KLF16 STAG3L2
Medication: Allopurinol 1.18 1 0 0.0 0.00 1.0e+00 WWP2
Mean time to correctly identify matches 1.78 3 2 6.1 0.00 1.0e+00 ADCY3 CCDC65 FOXO3
Whole body fat mass 3.29 26 18 54.5 -0.52 3.0e-03 ADCY3 AKTIP ARNTL ASPHD1 BYSL C11orf63 C14orf39 C3orf38 CTSW DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 MED20 NEGR1 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 SH3YL1 STAG3L2 WWP2
Leg fat mass (right) 3.51 22 18 54.5 -0.72 8.4e-05 ADCY3 AKTIP ARNTL ASPHD1 C3orf38 CTSW DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 NEGR1 PHF15 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 STAG3L2 WWP2
Arm predicted mass (right) 2.99 25 15 45.5 -0.07 7.2e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 CENPW CHP CTSW DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 RP3-467N11.1 TMEM110
Pulse rate, automated reading 2.28 16 5 15.2 -0.47 2.1e-02 BVES BYSL CCDC65 DAG1 GAB2 GPRC5B MED20 MSH6 NEGR1 PMS2P3 POM121C PRICKLE4 STAG3L2 TAF6 TMEM110 WWP2
Alcohol intake frequency. 1.32 5 2 6.1 -0.98 2.9e-03 ASPHD1 NEGR1 SENP6 STAG3L2 WWP2
Comparative height size at age 10 2.04 15 8 24.2 -0.57 2.7e-02 ADCY3 AKAP8 ASPHD1 BYSL C14orf39 CENPW FOXO3 FOXO6 LL22NC03-86G7.1 MED8 METTL15 NUCB2 SH3YL1 TOP3B WARS
Suffer from 'nerves' 1.57 3 2 6.1 0.00 1.0e+00 ANXA2 MADD SATB2
Overall health rating 1.56 4 1 3.0 0.94 6.1e-02 CTSW DAG1 DCAKD STAG3L2
Chest pain or discomfort 1.54 1 0 0.0 0.00 1.0e+00 DAG1
Age at last live birth 1.44 1 1 3.0 0.00 1.0e+00 DAG1
Leg pain on walking 1.06 1 0 0.0 0.00 1.0e+00 DAG1
Commuting to job workplace: Car/motor vehicle 1.08 1 0 0.0 0.00 1.0e+00 NEGR1
Illness, injury, bereavement, stress in last 2 years 1.06 1 0 0.0 0.00 1.0e+00 SNAP91
Supplements: Vitamin C 1.35 2 0 0.0 0.00 1.0e+00 PRICKLE4 WWP2
Knee pain experienced in last month 1.43 1 0 0.0 0.00 1.0e+00 DAG1
Hypertension (Self-reported) 1.99 16 3 9.1 -0.61 8.7e-03 ARNTL CHP DCAKD KLF16 MADD MAP2K5 NEGR1 NFAT5 NRBF2 NUCB2 PMS2P3 REXO1 RP11-613D13.5 STAG3L2 TAF6 WARS
Illnesses of father: Heart disease 1.49 1 0 0.0 0.00 1.0e+00 CHP
Smoking status: Previous 2.10 3 0 0.0 0.00 1.0e+00 MAP2K5 MSH6 WWP2
Forced expiratory volume in 1-second (FEV1), predicted 2.46 6 2 6.1 0.78 6.7e-02 BYSL C11orf63 C14orf39 CENPW HEMK1 LIN28B
Whole body fat-free mass 3.11 25 17 51.5 0.04 8.3e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 RP3-467N11.1 TMEM110
Leg fat-free mass (right) 3.26 26 15 45.5 -0.04 8.2e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 C9orf4 CENPW CTSW DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B LL22NC03-86G7.1 MADD MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 TMEM110
Arm fat percentage (left) 3.91 22 17 51.5 -0.71 7.5e-05 ADCY3 AKTIP ARNTL ASPHD1 CENPW CTSW GPRC5B KLF16 MADD MAP2K5 NEGR1 NFAT5 PHF15 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 STAG3L2 WWP2
Average weekly red wine intake 1.67 1 0 0.0 0.00 1.0e+00 NRBF2
Mood swings 1.30 1 0 0.0 0.00 1.0e+00 DAG1
Long-standing illness, disability or infirmity 2.42 3 0 0.0 0.00 1.0e+00 CHP NEGR1 STAG3L2
Ever had bowel cancer screening 1.93 1 1 3.0 0.00 1.0e+00 PRICKLE4
Diabetes diagnosed by doctor 1.59 4 0 0.0 -0.99 1.4e-02 AKTIP CENPW GCDH STAG3L2
Friendships satisfaction 1.49 1 0 0.0 0.00 1.0e+00 RP11-65J21.3
Qualifications: nursing, teaching 1.50 1 1 3.0 0.00 1.0e+00 NEGR1
Mineral and other dietary supplements 2.51 4 0 0.0 0.49 3.3e-01 BYSL MED20 NFAT5 PRICKLE4
Breast cancer (self-reported) 1.13 1 0 0.0 0.00 1.0e+00 HLF
Asthma (self-reported) 1.22 1 0 0.0 0.00 1.0e+00 EEFSEC
Smoking status: Current 1.64 2 0 0.0 0.00 1.0e+00 DPH2 PPP6C
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.23 2 0 0.0 0.00 1.0e+00 DAG1 WWP2
Whole body water mass 3.13 25 17 51.5 0.00 9.8e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 RP3-467N11.1 TMEM110
Leg predicted mass (right) 3.27 24 15 45.5 -0.01 9.4e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 C9orf4 CENPW DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 TMEM110
Arm fat mass (left) 3.93 24 20 60.6 -0.51 3.2e-03 ADCY3 AKTIP ARNTL ASPHD1 BYSL C3orf38 CTSW DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 MED20 NEGR1 PHF15 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 STAG3L2 WWP2
Number of self-reported non-cancer illnesses 1.78 4 2 6.1 -1.00 1.5e-04 ARNTL MAP2K5 NEGR1 STAG3L2
Miserableness 1.66 2 1 3.0 0.00 1.0e+00 ARNTL DAG1
Guilty feelings 1.73 2 1 3.0 0.00 1.0e+00 ARNTL LIN28B
Commuting to job workplace: Public transport 1.13 1 0 0.0 0.00 1.0e+00 NEGR1
Eye problems/disorders: Glaucoma 1.28 1 1 3.0 0.00 1.0e+00 C14orf39
Medication: Blood pressure 1.64 1 0 0.0 0.00 1.0e+00 CHP
Supplements: Fish oil (including cod liver oil) 1.82 2 0 0.0 0.00 1.0e+00 DCAKD NFAT5
High cholesterol (Self-reported) 1.52 2 1 3.0 0.00 1.0e+00 RP11-686O6.2 SPPL3
Medication: Paracetamol 1.16 2 0 0.0 0.00 1.0e+00 DAG1 DCAKD
Ever smoked 1.91 4 1 3.0 0.49 5.1e-01 DAG1 MSH6 PPP6C PSMG1
Basal metabolic rate 3.21 27 17 51.5 -0.01 9.6e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 C9orf4 CENPW CHP CTSW DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 RP3-467N11.1 TMEM110
Leg fat percentage (left) 3.26 24 14 42.4 -0.71 4.5e-05 ADCY3 AKTIP ARNTL ASPHD1 C3orf38 CENPW CTSW DAG1 DCAKD FOXO3 MADD MAP2K5 NEGR1 NRBF2 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 SENP6 STAG3L2 WWP2
Arm fat-free mass (left) 3.06 25 14 42.4 -0.10 5.9e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 CENPW CHP CTSW DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 RP3-467N11.1 TMEM110
Number of operations (self-reported) 1.48 2 0 0.0 0.00 1.0e+00 DAG1 LIN28B
Average weekly beer plus cider intake 2.58 5 0 0.0 -0.10 8.4e-01 BYSL DAG1 DCAKD NRBF2 PRICKLE4
Fractured/broken bones in last 5 years 1.10 1 0 0.0 0.00 1.0e+00 COG6
Diastolic blood pressure, automated reading 1.61 14 6 18.2 -0.64 1.0e-02 ARNTL CHP CTSW DCAKD GAB2 MAP2K5 MED8 NRBF2 PMS2P3 POM121C REXO1 STAG3L2 STXBP5 TAF6
Ever depressed for a whole week 1.00 1 0 0.0 0.00 1.0e+00 DAG1
Myopia 1.38 1 0 0.0 0.00 1.0e+00 SH3YL1
Vascular/heart problems diagnosed by doctor 1.94 12 4 12.1 0.82 5.6e-04 ARNTL CHP DCAKD KLF16 MADD MAP2K5 NEGR1 NFAT5 NUCB2 PMS2P3 RP11-613D13.5 STAG3L2
Cholesterol lowering medication 1.55 3 0 0.0 0.00 1.0e+00 NUCB2 RP11-686O6.2 SPPL3
Medication: Omeprazole (e.g. Zanprol) 2.33 2 0 0.0 -1.00 2.5e-05 BYSL MED20
Pain experienced in last month 1.57 4 2 6.1 -0.67 3.3e-01 CENPW DAG1 PPP6C RP11-613D13.5
Impedance of whole body 3.49 36 24 72.7 0.59 7.8e-05 ADCY3 AKTIP ASPHD1 BVES BYSL C3orf38 CENPW CTD-2623N2.11 CTSW DAG1 DCAKD DEGS2 DLGAP1-AS2 EEFSEC FOXO3 GAB2 GPRC5B HDHD2 HEMK1 KLF16 LIN28B MAP2K5 MED20 NEGR1 NRBF2 PHF15 PMS2P3 POM121C POPDC3 REXO1 RP3-467N11.1 SATB2 SFI1 STAG3L2 TMEM110 WARS
Leg fat mass (left) 3.55 22 19 57.6 -0.71 8.8e-05 ADCY3 AKTIP ARNTL ASPHD1 C3orf38 CTSW DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 NEGR1 PHF15 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 STAG3L2 WWP2
Arm predicted mass (left) 3.02 25 15 45.5 -0.07 6.9e-01 AKTIP ASPHD1 BYSL C14orf39 C3orf38 CENPW CHP CTSW DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 RP3-467N11.1 TMEM110

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 27 0.773 2.61
GTEx Adipose Visceral Omentum 20 0.982 2.61
GTEx Adrenal Gland 4 0.275 2.44
GTEx Artery Aorta 19 0.638 2.47
GTEx Artery Coronary 8 0.676 2.54
GTEx Artery Tibial 29 0.771 2.47
GTEx Brain Caudate basal ganglia 7 0.761 2.45
GTEx Brain Cerebellar Hemisphere 10 0.672 2.46
GTEx Brain Cerebellum 14 0.706 2.60
GTEx Brain Cortex 5 0.483 2.53
GTEx Brain Frontal Cortex BA9 7 0.758 2.61
GTEx Brain Hippocampus 1 0.191 2.49
GTEx Brain Hypothalamus 2 0.339 2.26
GTEx Brain Nucleus accumbens basal ganglia 4 0.462 2.42
GTEx Brain Putamen basal ganglia 3 0.481 2.30
GTEx Breast Mammary Tissue 17 0.861 2.47
GTEx Breast Mammary Tissue (Male) 5 0.419 2.17
GTEx Breast Mammary Tissue (Female) 10 0.608 2.36
GTEx Cells EBV-transformed lymphocytes 13 0.914 2.76
GTEx Cells Transformed fibroblasts 32 0.762 2.54
GTEx Colon Sigmoid 11 0.752 2.54
GTEx Colon Transverse 13 0.630 2.54
GTEx Esophagus Gastroesophageal Junction 9 0.623 2.57
GTEx Esophagus Mucosa 23 0.693 2.47
GTEx Esophagus Muscularis 24 0.743 2.56
GTEx Heart Atrial Appendage 15 0.950 2.60
GTEx Heart Left Ventricle 15 0.980 2.61
GTEx Liver 4 0.558 2.14
GTEx Lung 29 1.009 2.68
GTEx Muscle Skeletal 28 0.969 2.58
GTEx Nerve Tibial 33 0.764 2.53
GTEx Ovary 5 0.551 2.71
GTEx Pancreas 7 0.429 2.44
GTEx Pituitary 7 0.628 2.41
GTEx Prostate 5 0.599 2.54
GTEx Skin Not Sun Exposed Suprapubic 17 0.691 2.54
GTEx Skin Sun Exposed Lower leg 21 0.577 2.47
GTEx Small Intestine Terminal Ileum 5 1.085 2.41
GTEx Spleen 6 0.425 2.44
GTEx Stomach 14 0.963 2.58
GTEx Testis 22 0.697 2.41
GTEx Thyroid 26 0.650 2.57
GTEx Uterus 0 0.000 2.45
GTEx Vagina 1 0.157 2.44
GTEx Whole Blood 12 0.602 2.38
METSIM Adipose 23 0.499 2.20
NTR Blood 10 0.416 2.18
ROSMAP Brain Pre-frontal Cortex 45 1.025 2.43
YFS Blood 24 0.520 2.14
CommonMind Brain Pre-frontal Cortex 36 0.670 2.37
TCGA Breast Tumor 5 0.652 2.36
TCGA Breast Normal 25 0.594 2.20
TCGA Ovarian Tumor 17 0.582 2.15
TCGA Prostate Tumor 22 0.636 2.36